Fate Therapeutics Inc FATE:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:03 PM EDT
4.30UNCH (UNCH)
Volume
284,890
Close
4.30quote price arrow down-0.24 (-5.29%)
Volume
1,988,263
52 week range
1.63 - 8.83
Loading...
  • Open4.59
  • Day High4.66
  • Day Low4.17
  • Prev Close4.54
  • 52 Week High8.83
  • 52 Week High Date03/07/24
  • 52 Week Low1.63
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap486.642M
  • Shares Out113.17M
  • 10 Day Average Volume2.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change14.97

KEY STATS

  • Open4.59
  • Day High4.66
  • Day Low4.17
  • Prev Close4.54
  • 52 Week High8.83
  • 52 Week High Date03/07/24
  • 52 Week Low1.63
  • 52 Week Low Date10/30/23
  • Market Cap486.642M
  • Shares Out113.17M
  • 10 Day Average Volume2.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change14.97

RATIOS/PROFITABILITY

  • EPS (TTM)-1.63
  • P/E (TTM)-2.64
  • Fwd P/E (NTM)-2.17
  • EBITDA (TTM)-172.229M
  • ROE (TTM)-37.76%
  • Revenue (TTM)63.533M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-253.30%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Fate Therapeutics Inc

 

Profile

MORE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous...
William Rastetter Ph.D.
Independent Chairman of the Board
John Wolchko
President, Chief Executive Officer, Director
Edward Dulac III
Chief Financial Officer
Cindy Tahl J.D.
General Counsel and Corporate Secretary
Address
12278 Scripps Summit Drive
San Diego, CA
92131
United States

Top Peers

SYMBOLLASTCHG%CHG
CVAC
CureVac NV
2.51-0.09-3.46%
TBPH
Theravance Biopharma Inc
9.17-0.05-0.54%
OABI
OmniAb Inc
4.56-0.08-1.72%
EDIT
Editas Medicine Inc
5.35-0.11-2.01%
URGN
Urogen Pharma Ltd
14.21-0.32-2.20%